|
国际站:Secukinumab
CAS:1229022-83-6
品牌:MedChemExpress (MCE)
存储条件:Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性:苏金单抗 (AIN457) 是一种针对白细胞介素 (IL)-17A 的高亲和力人单克隆抗体。苏金单抗是一流的抗 IL-17 药物,用于斑块状银屑病、强直性脊柱炎和银屑病关节炎的研究[1][2]。
体外:苏金单抗是一种全人源单克隆抗体,可选择性结合并中和白细胞介素 17A[2]。苏金单抗(1 nM、10 nM 和 100 nM)可抑制 IL17A 和 IL17A/TNF a -诱导人星形胶质细胞中 IL6 蛋白水平的增加[3]。
参考文献:[1]. Shirley M, et al. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2016;76(11):1135-1145.[2]. Reich K, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304-315.[3]. Elain G, et al. The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia. 2014;62(5):725-735.
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-9-26 12:18
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社